EUVIMEDEUVIMED entdecken
Crossref

Modernizing Research and Evidence Consensus Definitions

Donna R Rivera, Tracy L Cutler, Lisa McShane, Ann Meeker-O'Connell, Hilary D Marston, Robert M Califf, Monica M Bertagnolli, FDA-NIH MoRE Glossary Working Group, Larissa Avilés-Santa, Kassa Ayalew, Ryan Bayha, Joshua Chetta und 32 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.16674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Donna R Rivera und 43 weiteren Autor:innen. Beteiligte Einrichtung: US Food and Drug Administration, Silver Spring, Maryland. Hauptthemen laut MEDLINE: Biomedical Research, National Institutes of Health (U.S.), Research Design, United States Food and Drug Administration. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The US Food and Drug Administration (FDA) and National Institutes of Health (NIH) share a mutual interest in facilitating efficient, well-designed clinical studies of drugs, devices, and biological products. Recent advances in science and technology, as well as innovative approaches to research design and methodology, provide opportunities to enhance efficiency in medical product development and improve participant engagement in clinical trials. Recent initiatives across the FDA and NIH focus on evidence modernization approaches. Fostering appropriate use of novel designs and sources of evidence, such as real-world data (RWD) to support marketing authorizations and satisfy postapproval study requirements, may be enhanced by using consensus terminology for innovative study designs.

Objective

To facilitate effective communication within the scientific community, FDA and NIH formed an interagency collaborative initiative to define clinical research terms related to innovative study designs, with a focus on studies using RWD, for FDA-regulated medical products or broader research and foster a shared understanding of terms across the clinical research ecosystem. Evidence Review The FDA-NIH Modernizing Research and Evidence (MoRE) Glossary Working Group (MGWG) was initiated in April 2023 to evaluate terms inadequately defined within the clinical research community that would benefit from development of a consensus definition. The MGWG conducted a landscape evaluation of common innovative design terminology that may lack clarity or concordance. Subsequently, the MGWG reviewed whether and how existing regulations, guidance, and policies use or define such terms. Following the landscape evaluation, the MGWG engaged in rigorous review to seek consensus definitions. In addition, federal agencies sought public input via a request for information before publishing the included terms and definitions.

Findings

The MGWG developed the MoRE Consensus Definitions, comprising 40 clinical research terms and definitions related to innovative clinical study designs that support scientific, patient, clinical, and regulatory decision-making. Conclusions and Relevance The MoRE Consensus Definitions are intended to facilitate effective communication about clinical research and enable transparency around innovative clinical study designs. This publication makes available the glossary developed through this collaboration and serves as an accessible resource for the clinical research enterprise. Furthermore, as clinical research is continuously evolving, additional efforts may focus on emerging new vocabulary and evolving use of current terms to benefit medical product development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomedical ResearchNational Institutes of Health (U.S.)Research DesignUnited States Food and Drug AdministrationHumansClinical Trials as TopicTerminology as TopicUnited States

Autor:innen und Institutionen

  • US Food and Drug Administration, Silver Spring, Maryland.
  • National Institutes of Health, Bethesda, Maryland.

Zitieren

APA

Rivera, D. R., Cutler, T. L., McShane, L., Meeker-O'Connell, A., Marston, H. D., Califf, R. M., Bertagnolli, M. M., FDA-NIH MoRE Glossary Working Group, Avilés-Santa, L., Ayalew, K., Bayha, R., Chetta, J., Concato, J., Culp, M., Dodd, L., Facey, N., Forshee, R., Freedman, A., Friedman, P., …, & Yongpravat, C. (2025). Modernizing Research and Evidence Consensus Definitions. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.16674

Vancouver

Rivera DR, Cutler TL, McShane L, Meeker-O'Connell A, Marston HD, Califf RM, et al. Modernizing Research and Evidence Consensus Definitions. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.16674

BibTeX
@article{Rivera2025,
  author = {Rivera, Donna R and Cutler, Tracy L and McShane, Lisa and Meeker-O'Connell, Ann and Marston, Hilary D and Califf, Robert M and Bertagnolli, Monica M and FDA-NIH MoRE Glossary Working Group, FDA-NIH MoRE Glossary Working Group and Avilés-Santa, Larissa and Ayalew, Kassa and Bayha, Ryan and Chetta, Joshua and Concato, John and Culp, Michelle and Dodd, Lori and Facey, Natasha and Forshee, Richard and Freedman, Andrew and Friedman, Philipa and Golfinopoulos, Elisa and Grandinetti, Cheryl and Jarman-Miller, Hannah and Jorgenson, Lyric and Karesh, Alyson and Kline, Lydia and Kluetz, Paul G and Kraus, Stefanie and Lee, Jennifer J and Lerro, Catherine C and Levenson, Mark and Li, Jie and Lu, Yun and Moore, Céline and Ordóñez, Anna E and Potter, Gail and Prindiville, Sheila and Rosenberg, Yves and Sarosy, Gisele and Shapley, Stephanie and Smith, Emily R and Talley, Anne and Tamburro, Robert and Viviano, Charles and Yongpravat, Charlie},
  title = {Modernizing Research and Evidence Consensus Definitions},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.16674}
}
Kostenlos starten →